Fresenius Medical Care AG & Co. KGaA (FMEA) - Net Assets

Latest as of March 2026: €14.20 Billion EUR ≈ $16.61 Billion USD

Based on the latest financial reports, Fresenius Medical Care AG & Co. KGaA (FMEA) has net assets worth €14.20 Billion EUR (≈ $16.61 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€31.47 Billion ≈ $36.79 Billion USD) and total liabilities (€17.26 Billion ≈ $20.18 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Fresenius Medical Care AG & Co. KGaA's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets €14.20 Billion
% of Total Assets 45.14%
Annual Growth Rate 3.06%
5-Year Change 2.17%
10-Year Change N/A
Growth Volatility 9.11

Fresenius Medical Care AG & Co. KGaA - Net Assets Trend (2016–2025)

This chart illustrates how Fresenius Medical Care AG & Co. KGaA's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Fresenius Medical Care AG & Co. KGaA to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Fresenius Medical Care AG & Co. KGaA (2016–2025)

The table below shows the annual net assets of Fresenius Medical Care AG & Co. KGaA from 2016 to 2025. For live valuation and market cap data, see FMEA stock market capitalisation.

Year Net Assets Change
2025-12-31 €14.28 Billion
≈ $16.70 Billion
-9.42%
2024-12-31 €15.77 Billion
≈ $18.44 Billion
+6.35%
2023-12-31 €14.83 Billion
≈ $17.33 Billion
-4.03%
2022-12-31 €15.45 Billion
≈ $18.06 Billion
+10.52%
2021-12-31 €13.98 Billion
≈ $16.34 Billion
+13.36%
2020-12-31 €12.33 Billion
≈ $14.42 Billion
-6.77%
2019-12-31 €13.23 Billion
≈ $15.46 Billion
+2.52%
2018-12-31 €12.90 Billion
≈ $15.08 Billion
+19.15%
2017-12-31 €10.83 Billion
≈ $12.66 Billion
-0.60%
2016-12-31 €10.89 Billion
≈ $12.74 Billion
--

Equity Component Analysis

This analysis shows how different components contribute to Fresenius Medical Care AG & Co. KGaA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 100.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings €12.21 Billion 91.72%
Other Components €1.10 Billion 8.28%
Total Equity €13.31 Billion 100.00%

Fresenius Medical Care AG & Co. KGaA Competitors by Market Cap

The table below lists competitors of Fresenius Medical Care AG & Co. KGaA ranked by their market capitalization.

Company Market Cap
Groep Brussel Lambert NV
BR:GBLB
$9.89 Billion
Harmony Gold Mining Company Limited
F:HAM
$9.89 Billion
CPFL Energia S.A
SA:CPFE3
$9.90 Billion
Mineral Resources Ltd
AU:MIN
$9.90 Billion
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
$9.88 Billion
Shandong Sinocera Func Material
SHE:300285
$9.84 Billion
KOC HOLDING ADR/5 TN 1
F:KRKA
$9.84 Billion
James Hardie Industries plc
F:JHA
$9.80 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Fresenius Medical Care AG & Co. KGaA's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 14,576,563,000 to 13,309,832,000, a change of -1,266,731,000 (-8.7%).
  • Net income of 978,367,000 contributed positively to equity growth.
  • Dividend payments of 422,515,000 reduced retained earnings.
  • Share repurchases of 585,285,000 reduced equity.
  • Other factors decreased equity by 1,237,298,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €978.37 Million +7.35%
Dividends Paid €422.51 Million -3.17%
Share Repurchases €585.28 Million -4.4%
Other Changes €-1.24 Billion -9.3%
Total Change €- -8.69%

Book Value vs Market Value Analysis

This analysis compares Fresenius Medical Care AG & Co. KGaA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.42x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 0.63x to 0.42x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €32.04 €20.20 x
2018-12-31 €38.32 €20.20 x
2019-12-31 €40.08 €20.20 x
2020-12-31 €38.29 €20.20 x
2021-12-31 €47.71 €20.20 x
2022-12-31 €52.65 €20.20 x
2023-12-31 €46.42 €20.20 x
2024-12-31 €49.68 €20.20 x
2025-12-31 €47.66 €20.20 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Fresenius Medical Care AG & Co. KGaA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 7.35%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 4.98%
  • • Asset Turnover: 0.63x
  • • Equity Multiplier: 2.33x
  • Recent ROE (7.35%) is below the historical average (8.78%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 11.50% 6.94% 0.66x 2.49x €154.41 Million
2017 13.03% 7.20% 0.74x 2.45x €297.78 Million
2018 16.86% 11.98% 0.63x 2.23x €806.08 Million
2019 10.03% 6.86% 0.53x 2.75x €3.83 Million
2020 10.38% 6.52% 0.56x 2.83x €42.87 Million
2021 6.93% 5.50% 0.51x 2.46x €-428.90 Million
2022 4.36% 3.47% 0.54x 2.31x €-871.90 Million
2023 3.66% 2.57% 0.57x 2.49x €-863.03 Million
2024 3.69% 2.78% 0.58x 2.30x €-919.74 Million
2025 7.35% 4.98% 0.63x 2.33x €-352.62 Million

Industry Comparison

This section compares Fresenius Medical Care AG & Co. KGaA's net assets metrics with peer companies in the Medical Care Facilities industry.

Industry Context

  • Industry: Medical Care Facilities
  • Average net assets among peers: $5,818,583,050
  • Average return on equity (ROE) among peers: -78.31%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Fresenius Medical Care AG & Co. KGaA (FMEA) €14.20 Billion 11.50% 1.22x $9.88 Billion
China Resources Medical Holdings Company Limited (1PH) $6.14 Billion 6.37% 0.28x $405.05 Million
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) $-125.88 Million 0.00% 0.00x $3.30 Million
JINXIN FERT.GRP HD-00001 (3NX) $10.19 Billion 3.38% 0.46x $656.44 Million
REVITALIST L.A.W. LTD (4DO) $1.87 Million -771.24% 4.54x $744.60K
Wenzhou Kangning Hospital Co. Ltd (4WK) $1.21 Billion 6.69% 0.53x $17.43 Million
HYGEIA HC HLDGS DL-00001 (50I) $6.67 Billion 8.96% 0.64x $9.61K
COMPASS PATHW SP.ADR (5Y6) $225.74 Million -52.48% 0.22x $657.30 Million
Bumrungrad Hospital Public Company Limited (BZ7A) $31.17 Billion 24.10% 0.17x $50.75K
Eifelhöhen-Klinik AG (EIF) $9.88 Million -19.11% 6.64x $10.05 Million
Fresenius Medical Care AG & Co. KGaA (FME) $2.70 Billion 10.24% 1.40x $10.01 Billion

About Fresenius Medical Care AG & Co. KGaA

F:FMEA Germany Medical Care Facilities
Market Cap
$12.68 Billion
€10.85 Billion EUR
Market Cap Rank
#2287 Global
#469 in Germany
Share Price
€20.20
Change (1 day)
+3.59%
52-Week Range
€17.70 - €24.20
All Time High
€37.68
About

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arr… Read more